Comparing Protagonist Therapeutics (NASDAQ:PTGX) and Genelux (NASDAQ:GNLX)

Genelux (NASDAQ:GNLX) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Analyst Recommendations

This is a summary of current recommendations for Genelux and Protagonist Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1	0	3	1	2.80
Protagonist Therapeutics	0	1	17	0	2.94

Genelux presently has a consensus price target of $18.00, indicating a potential upside of 605.88%. Protagonist Therapeutics has a consensus price target of $154.44, indicating a potential upside of 6.60%. Given Genelux’s higher probable upside, analysts clearly believe Genelux is more favorable than Protagonist Therapeutics.

Volatility & Risk

Genelux has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.

Profitability

This table compares Genelux and Protagonist Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Insider & Institutional Ownership

37.3% of Genelux shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Genelux and Protagonist Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$8,000.00	14,421.84	-$32.15 million	($0.86)	-2.97
Protagonist Therapeutics	$46.02 million	203.72	-$130.15 million	$1.03	140.66

Genelux has higher earnings, but lower revenue than Protagonist Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Protagonist Therapeutics beats Genelux on 10 of the 15 factors compared between the two stocks.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.